TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

doi:10.1158/1078-0432.CCR-18-0163

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Nov 2018

Biton Jérôme, Mansuet-Lupo Audrey, Pécuchet Nicolas, Alifano Marco, Ouakrim Hanane, Arrondeau Jennifer, Boudou-Rouquette Pascaline, Goldwasser François, Leroy Karen, Goc Jeremy, Wislez Marie, Germain Claire, Laurent-Puig Pierre, Dieu-Nosjean Marie-Caroline, Cremer Isabelle, Herbst Ronald, Blons Hélène, Damotte Diane

Abstract excerpt

Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1 (PD-1) exhibit impressive clinical results in non-small cell lung cancer, underlining the strong interactions between tumor and immune cells. However, factors that can robustly predict long-lasting responses are still needed.Experimental Design: We performed in-depth immune profiling of lung adenocarcinoma using an integrative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinase Kinases

Share to Antigen Presentation

Share to Antineoplastic Agents, Immunological

Share to Chemotaxis, Leukocyte

Share to Cytotoxicity, Immunologic

Share to Immunomodulation

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed

Identifiers

PMID: 29764856
DOI: 10.1158/1078-0432.CCR-18-0163

Genes

EGFR
STK11
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.PMID 29764856Read ↗

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.Semantic proximity Read ↗

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Semantic proximity Read ↗

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.Semantic proximity Read ↗

Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.Semantic proximity Read ↗

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Semantic proximity Read ↗

<i>STK11</i> and <i>KEAP1</i> Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma CohortSemantic proximity Read ↗

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy.Semantic proximity Read ↗

Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.Semantic proximity Read ↗

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.Semantic proximity Read ↗

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.